Table 5 Predictive factors of work ability perception at the enrolment
From: Quality of life and work functionality in severe asthma patients: the impact of biological therapies
Features | N | Beta | 95% CI | P-value |
|---|---|---|---|---|
Gender | 30 | |||
F | - | - | ||
M | 0.95 | -4.1, 6.0 | 0.705 | |
Age | 30 | -0.29 | -0.55, -0.03 | 0.033 |
Age at diagnosis | 30 | -0.02 | -0.20, 0.17 | 0.845 |
BMI | 30 | 0.22 | -0.44, 0.88 | 0.504 |
Smoke | 30 | 0.05 | -3.4, 3.5 | 0.979 |
Education level | 30 | |||
A | - | - | ||
B | 1.7 | -3.3, 6.8 | 0.487 | |
C | 7.4 | 1.9, 13 | 0.010 | |
Atopy | 30 | 0.14 | -4.8, 5.0 | 0.954 |
Nasal polyposis | 30 | -2.0 | -6.7, 2.7 | 0.396 |
Drug | 30 | |||
Benralizumab | - | - | ||
Dupilumab | 1.3 | -4.2, 6.8 | 0.635 | |
Mepolizumab | -1.3 | -8.2, 5.5 | 0.693 | |
Relapses in the previous 12 months | 30 | -0.57 | -4.2, 3.0 | 0.747 |
ACT | 30 | 0.31 | -0.63, 1.3 | 0.502 |
Spirometric values (M ± SD) | ||||
FEV1 (L) | 30 | 3.8 | -0.69, 8.2 | 0.094 |
FEV1 (%) | 30 | 0.22 | 0.04, 0.40 | 0.020 |
FVC (L) | 30 | 1.1 | -1.4, 3.7 | 0.362 |
FVC% | 30 | 0.16 | -0.05, 0.36 | 0.132 |
FEV1/FVC | 30 | 0.10 | -0.13, 0.32 | 0.386 |
FeNO (ppb) | 30 | 0.03 | -0.35, 0.40 | 0.879 |
Eosinophils (n/μL) | 30 | 0.01 | 0.00, 0.02 | 0.144 |
Eosinophils % | 30 | 0.55 | -0.30, 1.4 | 0.193 |
Current work duration (years) | 30 | -0.04 | -0.24, 0.16 | 0.677 |
Type of contract | 30 | |||
Permanent | - | - | ||
Fixed-term | -3.4 | -9.0, 2.1 | 0.212 | |
Freelance | 2.2 | -3.9, 8.3 | 0.468 | |
Sector | 30 | |||
Private | - | - | ||
Public | -1.1 | -6.2, 4.0 | 0.661 | |